Overexpression of melanocortin 2 receptor accessory protein 2 (MRAP2) in adult paraventricular MC4R neurons regulates energy intake and expenditure

Giuseppe Bruschetta1,2, Jung Dae Kim1,2, Sabrina Diano1,2,3,4,5,*, Li F. Chan6,*

ABSTRACT

Objective: Melanocortin 2 receptor accessory protein 2 (MRAP2) has a critical role in energy homeostasis. Although MRAP2 has been shown to regulate a number of GPCRs involved in metabolism, the key neurons responsible for the phenotype of gross obesity in MRAP2 deficient animals are unclear. Furthermore, to date, all the murine MRAP2 models involve the prenatal deletion of MRAP2.

Methods: To target Melanocortin 4 receptor (MC4R)-expressing neurons in the hypothalamic paraventricular nucleus (PVN), we performed stereotaxic surgery using AAV to selectively overexpress MRAP2 postnatally in adult Mc4r-cre mice. We assessed energy homeostasis, glucose metabolism, core body temperature, and response to MC3R/MC4R agonist MTII.

Results: Mc4r-crePVMRAP2 female mice on a standard chow diet had less age-related weight gain and improved glucose/insulin profile compared to control Mc4r-crePVMC4R mice. These changes were associated with a reduction in food intake and increased energy expenditure. In contrast, Mc4r-crePVMRAP2 male mice showed no improvement on a chow diet, but improvement of energy and glucose metabolism was observed following high fat diet (HFD) feeding. In addition, an increase in core body temperature was found in both females fed on standard chow diet and males fed on HFD. Mc4r-crePVMRAP2 female and male mice showed increased neuronal activation in the PVN compared to controls, with further increase in neuronal activation post MTII treatment in females.

Conclusions: Our data indicate a site-specific role for MRAP2 in PVN MC4R-expressing neurons in potentiating MC4R neuronal activation at baseline conditions in the regulation of food intake and energy expenditure.

Keywords MRAP2; MC4R; Food intake; Energy homeostasis; Obesity

1. INTRODUCTION

MRAP2 is predominantly expressed in the hypothalamus, in particular within the paraventricular nucleus (PVN), a region known to express MC4R and with a critical role in energy homeostasis [1–3]. Mice with global MRAP2 deletion and conditional MRAP2 deletion in SIM1 expressing neurons developed marked obesity, while rare loss-of-function or missense heterozygous variants in MRAP2 were identified in humans with severe early-onset obesity [4,5]. MRAP2’s critical role in the control of energy homeostasis has been linked to action on MC4R signaling [4,6]. Further evidence that MRAP2 acts via MC4R signaling came from a study on the role of Mrap2 in zebrafish feeding and growth [7].

Although data point to an MC4R dependent function, Mrap2−/− mice do not fully phenocopy the Mc4r−/− mice. In particular, there is the paradox that while Mrap2−/− mice become obese without detectable changes in food intake or energy balance, Mc4r−/− mice have hyperphagia and reduced energy expenditure (EE) [8,9]. Mrap2−/− mice remain responsive to treatment with MTII, a MC3R/MC4R agonist, while the anorexic response to MTII is abolished in Mc4r−/− mice, suggesting at least some preservation of MCR function centrally [4,10]. The phenotype of gross, early onset obesity without detectable change of food intake and energy expenditure, replicated in an independent Mrap2 deficient model, is particularly intriguing [4,6]. However, the mechanism by which MRAP2 knockout animals become obese is still unclear. Plasma corticosterone, thyroid function, faecal energy measurements, body temperature, and brown fat function in response to...
cold challenge were all indistinguishable between Mrap2/−/− and Mrap2+/+/ mice [4,6]. Some of the complexity may arise from the fact that MRAP2 is a promiscuous accessory protein [1]. In addition to the melanocortin receptor family (MCRI) [11], MRAP2 interacts and regulates other G Protein-Coupled Receptors (GPCRs) beyond the MCR family [1,12–14]. Interaction with Prokineticin 1 receptor, orexin 1 receptor, and Ghsr receptor have been reported [12–14]. However, these interactions would result in a lean phenotype in the absence of MRAP2. Thus, while interaction with these additional GPCRs forms part of the growing understanding of MRAP2 action in the neuronal control of energy homeostasis, it does not explain the obese phenotype of MRAP2 deficient animals.

With data pointing to the PVN and MC4R as the key to unraveling the obesity phenotype in MRAP2 deficient mice and because all existing mouse models to date involve developmental deletion of MRAP2, we undertook this study to assess the effect of postnatal overexpression of MRAP2 in MC4R neurons of the PVN. Furthermore, using this methodology we are able to exclude the effects of MRAP2 interaction with non-PVN MC4R GPCRs, in particular those GPCRs that have been described to interact with MRAP2 in the arcuate nucleus [12–14].

2. MATERIAL AND METHODS

2.1. Ethics and animal husbandry

All animal studies on male and female mice were approved by Yale University Institutional Animal Care and Use Committee. Animals had free access to water and food provided ad libitum, unless otherwise stated. Mice were fed on a standard chow diet (SD) (diet no. 2018; 18% calories from fat; Teklad Diets, Harlan Laboratories) for up to 6 months of age. For high fat diet (HFD) experiments, male mice were exposed to HFD (category no. 93075; 45% fat; Teklad Diets, Harlan Laboratories) starting at 2 weeks after PVN injection. All animals were kept in temperature and humidity-controlled rooms, in a 12 h dark and 12 h light cycle, with lights on from 7:00 AM to 7:00 PM.

2.2. Generation of Mc4r-2A-cre mice and genotyping

Mc4r-2A-cre mice were generated as previously described [15]. Genomic DNA was isolated from tails or yolk sacs by standard methods. Mc4r-2A-cre mice were genotyped by polymerase chain reaction (PCR parameters: 42 cycles, 93 °C for 30 s, 56 °C for 1 min, and 72 °C for 5 min). Amplification of a wild-type (WT) allele generated a 3.6-kb product, and a 4.1-kb product in the case of a mutant allele using the following primers: cre 350 FRT5: 5′-ctgtcacttggtcggca-3′, Mc4r-2A-creStop F1: 5′-gatacgtgtacgctgc-3′, Mc4r-2A-creStop F1: 5′-ctgtcacttctaaagccc-3′.

2.3. Stereotaxic viral injection of Adeno-associated virus (AAV) into the PVN

The AAV2-CMV-DIO-GFP [AAV-DIO-GFP] and AAV2-CMV-DIO-MRAP2-FLAG [AAV-DIO-MRAP2] virus (VECTOR BIOABS) were injected bilaterally into the PVN of Mc4r-cre animals. Moreover AAV2-CMV-GFP (VECTOR BIOABS cat no. 70094) virus was co-injected to determine successful PVN targeting. Eight weeks old Mc4r-cre mice were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine (IP) and placed in stereotaxic apparatus. A guide cannula with dummy cannula (Plastics one, Roanoke, VA) was inserted into the PVN according to the atlas of Franklin and Paxinos (Franklin KBJ) (co-ordinates, bregma: anterior-posterior −0.7 mm; lateral ±0.2 mm; and dorsal–ventral −5.2 mm), virus was infused at a rate of 40 nl/min (~2 × 1012 viral particles/μL) for 15 min and the injector (Plastics one) remained in place for an additional 5 min before the injector was connected with a Hamilton syringe and infusion was administered at a rate of 33.3 nL/min.

2.4. GFP immunostaining

Fed mice were perfused and brains were processed for immunofluorescence staining to confirm the injection site in the PVN, using anti-GFP antibody (ab13970; Abcam). Mice in which viral injections were located outside the PVN were studied separately. The sections were incubated overnight in anti-GFP antibody (diluted 1:5000 in 0.1 mol/L sodium phosphate buffer) and then incubated in secondary antibody (category no. A11039, Alexa Fluor 488—coupled goat anti-chicken, 1:500 dilution; Life Technologies) for 2 h. Sections were then analyzed with fluorescent microscope.

2.5. FLAG immunostaining

Immunofluorescence staining was performed using anti-FLAG antibody (F1804; Sigma). Brains were sectioned with a vibratome, and sections were incubated for 24 h at room temperature in anti-FLAG antibody (diluted 1:2000). After several washes with phosphate buffer (PB), sections were incubated in secondary antibody (category no. BA 2000 biotinylated horse anti-mouse IgG; 1:200 in PB; Vector Laboratories) for 2 h at room temperature, then rinsed in PB three times 10 min each time, and incubated for 2 h at room temperature with Alexa Fluor 594 streptavidin (Life Technologies, 1:2000 in PB). Sections were mounted on glass slide with vectashield (Vector lab) and analyzed with fluorescent microscope.

2.6. Indirect calorimetry system and body composition

Body weight was measured weekly after stereotaxic surgery. Body composition was measured in vivo by MRI (EchoMRI; Echo Medical Systems, Houston, TX). Twelve weeks after PVN injection male and female mice were acclimated in metabolic chambers (TSE Systems, Germany) for 4 days before the start of the recordings. Animals were continuously recorded for 3 days with the following measurements being taken every 30 min. Measurements include food intake, locomotor activity (in X and Y axes), and gas exchange (O2 and CO2) every 30 min using the TSE LabMaster System. Respiratory exchange ratio (RER) was calculated as a ratio of CO2 production and O2 consumption. Energy expenditure (EE) was calculated according to the manufacturer’s guidelines (PhenoMaster Software, TSE Systems) and analyzed relative to body weight using ANCOVA analysis [16]. Food intake was determined continuously using weighing sensors integrated within the sealed cage.

2.7. Glucose and insulin tolerance tests

Glucose tolerance test (GTT) was performed using 2 mg/kg glucose in saline (DeltaSelect) given intraperitoneally (IP) to 16 h fasted animals as previously described [17]. Blood glucose levels were then monitored at 15, 30, 60, and 120 min from the injection. Insulin tolerance test (ITT) was performed using an insulin dose of 0.75 U/kg (Actrapid; Novo Nordisk A/S Denmark) delivered by IP in mice fed ad libitum. Blood glucose was measured before IP injection and at 15, 30, 60, and 120 min after insulin injection.

2.8. cfos immunostaining

Ad libitum fed mice were anesthetized and transcardially perfused with 0.9% saline with heparin followed by 4% paraformaldehyde. In another set of experiments, mice were injected with either MTII (200 nM, IP) or equal volume saline. Animals were perfused 1 h post injection. Brains were collected and post-fixed overnight before several sections of the entire hypothalamus were taken at every
50 μm. Sections were washed and incubated with the goat anti-cfos antibody (Santacruz, 1:2000), and rabbit anti-POMC antibody (Phoenix Pharmaceuticals, 1:2000) in PB containing 4% normal donkey serum, and 1% Triton X-100 for 24 h at room temperature. After several washes with phosphate buffer (PB), sections were incubated in the secondary antibodies (biotinylated donkey anti-goat immunoglobulin G [IgG]; 1:200 in PB; Vector Laboratories and donkey anti-rabbit Alexa-fluor 488; 1:500 in PB; Life Technologies) for 2 h at room temperature, then rinsed in PB five times, 10 min each time. Sections were then mounted on glass slide with VectaShield antifade (Vector Laboratories). Fluorescent images of five to seven brain sections were captured with fluorescent microscope and analyzed by imaging Software (Image J).

2.9. Real-time RT PCR
Total RNA from brown adipose tissue was extracted from Mc4r-crePVN-MRAP2 and control mice using Trizol solution (Invitrogen). Uncoupling protein 1 (UCP1) and Deiodinase 2 (DIO2) mRNA levels in the brown adipose tissue, were measured by real-time PCR. A High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used for the reverse transcription. Real-time PCR (LightCycler 480; Roche) was performed with diluted cDNAs in a 20-μl reaction volume in triplicates. Primers used for this study are as follows: cat. No. Mm 01244861_m1 for UCP1, cat. No Mm 00515664_m1 for DIO2, and Mm 02619580_g1 for β-actin (Applied Biosystems). The calculations of average Cq values, SDs, and resulting expression ratios for each target gene were based on the Roche LightCycler 480 software.

2.10. Statistical analysis
All statistical analysis was performed using GraphPad Prism. Data is plotted as mean ± S.E.M. Student’s t test was used to compare two groups; for more than two groups one-way ANOVA was performed followed by Bonferroni multiple comparison test. In all analyses, a two-tailed probability of <5% (i.e., P < 0.05) was considered statistically significant.

3. RESULTS

3.1. Postnatal overexpression of MRAP2 in PVN MC4R expressing neurons alters metabolism selectively in female Mc4r-crePVN-MRAP2 mice on a chow diet
To assess the role of MRAP2 in the MC4R-expressing neurons of the PVN postnatally, we injected an AAV-DIO-MRAP2 and its control, AAV-DIO-GFP, in the PVN of female (Figure S1A–B) and male (Figure S1D–E) Mc4r-cre mice [15]. Moreover, to assess the overexpression of MRAP2 in the PVN, immunostaining for FLAG epitope was performed in female (Figure S1C) and in male Mc4r-crePVN-MRAP2 mice (Figure S1F). To determine whether selective MRAP2 overexpression in PVN MC4R affects metabolism, metabolic analyses were performed in both male and female mice. Mc4r-crePVN-MRAP2 female mice fed on a standard chow diet showed lower body weight (n = 11 per group; Figure 1A) starting at 3 weeks from the viral injections compared with Mc4r-crePVN-GFP controls. The lower body weight was due to a significant reduction of fat mass (4.49 ± 0.61 g n = 11; Figure 1B) in Mc4r-crePVN-MRAP2 female mice compared to female controls (7.80 ± 0.51 g Mc4r-crePVN-GFP female mice; n = 11) evidenced after 4 weeks post viral injections. No differences in lean mass were observed between the 2 experimental groups (n = 11; Figure 1C). This was associated with decreased food intake (2.79 ± 0.10 g in female Mc4r-crePVN-MRAP2 mice and 3.35 ± 0.22 g in female Mc4r-crePVN-GFP controls; Figure 1D–E) specifically during the dark period (2.41 ± 0.23 g in controls vs 1.89 ± 0.10 g in Mc4r-crePVN-MRAP2 female mice; n = 8 and 11, respectively; Figure 1D–E). Furthermore, increases in locomotor activity (37.74 ± 2138 beam break counts in controls vs 55.91 ± 7631 beam break counts in Mc4r-crePVN-MRAP2 female mice; n = 8 and 10, respectively; Figure 1F) and energy expenditure (Figure 1G–I) were also observed in Mc4r-crePVN-MRAP2 female mice compared to female controls. vO2 was also different between Mc4r-crePVN-MRAP2 female mice (3195.63 ± 101.02 ml per day) and controls (2890.92 ± 80.74 ml per day, Figure 1J), while no differences in vCO2 (2430.37 ± 104.96 ml per day in controls vs 2715.73 ± 113.60 ml per day in Mc4r-crePVN-MRAP2 mice; Figure 1K–L) between the experimental groups. In agreement with the improved metabolic phenotype, both glucose (Figure S2A) and insulin tolerance tests (Figure S2B) were significantly improved in Mc4r-crePVN-MRAP2 female mice compared to female Mc4r-crePVN-GFP controls. Arcuate POMC cells are known to activate MC4R-expressing neurons in the PVN, inhibiting food intake and increasing energy expenditure. To ensure that the observed improved metabolic phenotype was not due to a differential activation of POMC neurons, we quantified PVN POMC fiber density (1386.35 ± 147.24 in controls vs 1478.14 ± 83.66 in Mc4r-crePVN-MRAP2 n = 6; Figure S3A–C) and arcuate nucleus neuronal activation, including POMC (43.78 ± 1.47 in controls vs 46.27 ± 1.36 in Mc4r-crePVN-MRAP2 n = 6, cfos positive POMC neurons; 36.41 ± 1.74 in controls vs 39.08 ± 2.76 in Mc4r-crePVN-MRAP2 female mice per group, cfos positive cells in the ARC; Figure S3D and E), and found no difference between Mc4r-crePVN-MRAP2 and Mc4r-crePVN-GFP female mice. In addition, a significant increase in body temperature was also found in Mc4r-crePVN-MRAP2 female mice (37.65 ± 0.15 °C) compared to Mc4r-crePVN-GFP female mice (37.04 ± 0.16 °C; Figure 2A) that was associated with significant increases in UCP1 (Figure 2B) and Dio2 (Figure 2C) mRNA levels in the BAT. Altogether, these data indicate that MRAP2 in PVN MC4R neurons affects energy metabolism in female mice.

3.2. Selective MRAP2 overexpression in PVN MC4R neurons induced increased PVN neuronal activation, which is further affected by MTII administration, in female mice
As MRAP2 overexpression in PVN-MC4R neurons in adult female mice led to a leaner phenotype, to determine the effect of MRAP2 overexpression on PVN neuronal activation, we performed and quantified cfos immunostaining in the PVN of Mc4r-crePVN-MRAP2 and Mc4r-crePVN-GFP female mice. A significant increase of cfos immunoreactivity was found in Mc4r-crePVN-MRAP2 female mice (59.97 ± 3.88 cfos positive cells/section; n = 6 Figure 3B, E) compared to Mc4r-crePVN-GFP female mice (44.20 ± 1.39 cfos positive cells/section; n = 5 Figure 3A, E). Furthermore, when MTII, a MC3R/MC4R agonist, was peripherally injected, no difference in food intake (Figure 3F) and cfos activation in the PVN (Figure 3C–E) was observed between Mc4r-crePVN-GFP and Mc4r-crePVN-MRAP2 female mice (1.49 ± 0.46 g and 138.24 ± 13.35 cfos positive cells/section in controls vs 1.48 ± 0.31 g and 116.54 ± 12.08 cfos positive cells/section in Mc4r-crePVN-MRAP2 female mice; n = 4 per group; Figure 3E). Comparing saline and MTII treated Mc4r-crePVN-MRAP2 female mice, a statistical difference was noted in food intake and cfos positive cells (59.97 ± 3.88 cfos positive cells/section; n = 6 compared with 116.54 ± 12.08 cfos positive cells/section in Mc4r-crePVN-MRAP2 female mice; n = 4 per group Figure 3E, F).
3.3. Selective overexpression of MRAP2 in MC4R neurons does not alter energy metabolism in male mice on a standard chow diet.

Due to the clear phenotype in female mice, we then studied male mice and, interestingly, no significant differences in body weight (Figure S4A), fat mass (7.84 ± 0.94 g in controls vs 7.38 ± 1.53 g in Mc4r-crePVN-MRAP2 n = 6 per group, 12 weeks after injection in the PVN; Figure S4B), and lean mass (22.39 ± 0.50 g in controls vs 21.76 ± 0.94 g in Mc4r-crePVN-MRAP2 n = 6 per group, 12 weeks after injection in the PVN; Figure S4C) were observed in male mice on a standard chow diet. In addition, no changes in glucose tolerance test (Figure S4D), insulin tolerance test (Figure S4E), and body temperature (36.42 ± 0.13 °C in controls vs 36.54 ± 0.37 °C in Mc4r-crePVN-MRAP2 mice) were observed in male mice three months after the PVN viral injections. All data are presented as mean ± SEM. *P < 0.05; **P < 0.01 compared to Mc4r-crePVN-GFP mice.

Figure 1: Selective overexpression of MRAP2 in the PVN MC4R neurons affects metabolism in female mice. (A–C) Graphs showing body weight (A), fat mass (B), and lean mass (C) of Mc4r-crePVN-GFP control female mice (n = 11) and Mc4r-crePVN-MRAP2 (n = 11) female mice at 4, 8 and 12 weeks after injection. (D and E) Graphs showing food intake in Mc4r-crePVN-GFP female mice (n = 8) and Mc4r-crePVN-MRAP2 female mice (n = 10). Total cumulative food intake in the 24 h cycle is shown (D) and in the dark and light phases of the cycle (E). Gray area in D represents the dark phase. (F–I) Graphs showing locomotor activity (F) and total energy expenditure in the 24-h period (G) and in the dark (H) and light (I) phases of the cycle of Mc4r-crePVN-GFP (n = 8) and Mc4r-crePVN-MRAP2 mice (n = 10) three months after the PVN viral injections. (J–L) Graphs showing O2 consumed (J), CO2 produced (K), and the ratio in (L) of Mc4r-crePVN-GFP (n = 8) and Mc4r-crePVN-MRAP2 mice (n = 10) three months after the PVN viral injections. All data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 compared to Mc4r-crePVN-GFP mice.

Figure 2: Effects of PVN-MRAP2 overexpression in MC4R expressing neurons on body temperature and brown adipose tissue of female mice. (A) Graph showing body temperature in Mc4r-crePVN-GFP female mice (n = 7) and Mc4r-crePVN-MRAP2 female mice (n = 7) three months after PVN viral injections. (B and C) Graphs showing Real-Time RT PCR data for Ucp1 (B) and Dio2 (C) in brown adipose tissue of female Mc4r-crePVN-GFP (n = 7) and Mc4r-crePVN-MRAP2 mice (n = 7) three months after PVN viral injections. All data are presented as mean ± SEM. *P < 0.05; **P < 0.01 compared to Mc4r-crePVN-GFP mice.
Figure 3: Selective overexpression of MRAP2 in MC4R expressing neurons in the PVN affects neuronal activation in female mice which is further increased with MTII administration. (A and B) Representative hypothalamic sections from a female Mc4r-crePVN-MRAP2 (A) and a female Mc4r-crePVN-GFP mouse both injected IP with saline (B) immunostained for cfos (red) in the hypothalamic paraventricular nucleus (PVN). (C and D) Representative hypothalamic PVN sections immunostained for cfos from a Mc4r-crePVN-MRAP2 (C) and a Mc4r-crePVN-GFP mouse (D) following IP injection with MTII. (E) Quantification of cfos expression in the PVN of Mc4r-crePVN-MRAP2 (n = 5) and Mc4r-crePVN-GFP female mice (n = 4) three months after the PVN viral injections. A significant difference is noted between saline treated and MTII treated animals in both groups. 3v = third ventricle; PVN = paraventricular nucleus of the hypothalamus. Bar scale in A–D represents 100 μm. All data are presented as mean ± SEM. **P < 0.01 compared to Mc4r-crePVN-GFP mice.

n = 6 per group; Figure S4F) were observed between Mc4r-crePVN-GFP and Mc4r-crePVN-MRAP2 male mice exposed to a standard chow diet. However, when exposed to high fat diet (45% of fat), male Mc4r-crePVN-MRAP2 mice showed lower body weight gain compared to control male Mc4r-crePVN-GFP mice (Figure 4A; n = 6 per group). This difference was due to a significant reduction in fat mass (24.75 ± 1.01 g in controls vs 21.66 ± 0.79 g in Mc4r-crePVN-MRAP2; n = 6 per group, 8 weeks on HFD; Figure 4B). No significant changes in lean mass were found (24.51 ± 0.60 g in controls vs 25.57 ± 1.24 g in Mc4r-crePVN-MRAP2; n = 6 per group, 8 weeks on HFD; Figure 4C). Food intake analysis showed a significant reduction of feeding in Mc4r-crePVN-MRAP2 male mice compared to control mice specifically during the dark phase (1.81 ± 0.19 g in controls vs 0.82 ± 0.29 g in Mc4r-crePVN-MRAP2; n = 6 per group; Figure 4D and E). In addition, locomotor activity (20.77 ± 1.747 beam break counts in controls vs 33.736 ± 5.222 beam break counts in Mc4r-crePVN-MRAP2; n = 6 per group; Figure 4F) and energy expenditure (11.699 ± 0.615 kcal per day in controls vs 12.937 ± 0.715 kcal per day in Mc4r-crePVN-MRAP2; n = 6 per group; Figure 4G–H) analyses also showed significant increases in Mc4r-crePVN-MRAP2 male mice compared to Mc4r-crePVN-GFP male mice. In agreement with an overall improved metabolic phenotype, glucose (Figure S5A) and insulin tolerance (Figure S5B) tests were also improved in Mc4r-crePVN-MRAP2 male mice compared to Mc4r-crePVN-GFP male mice. Finally, similar to females, MRAP2 overexpression in MC4R neurons of the PVN induced a significant decrease in body temperature (36.83 ± 0.11 °C in controls vs 37.37 ± 0.17 °C in Mc4r-crePVN-MRAP2; n = 7 per group; Figure S5A) that was accompanied by greater BAT UCP1 (Figure S5B) and Dio2 (Figure S5C) mRNA levels. Finally, to test that the observed improved metabolic phenotype was not due to a differential activation of POMC neurons, we quantified PVN POMC fiber density (1261.03 ± 31.45 in controls vs 1157.57 ± 86.70 in Mc4r-crePVN-MRAP2; n = 6 per group; Figure S5A–C) and arcuate nucleus neuronal activation, including POMC (36.11 ± 2.53 in controls vs 40.97 ± 3.59 in Mc4r-crePVN-MRAP2; n = 6 per group, cfos positive POMC neurons; 50.04 ± 2.32 in controls vs 47.85 ± 4.60 in Mc4r-crePVN-MRAP2; n = 6 per group, cfos positive cells in the ARC; Figure S6D and E), and found no difference between Mc4r-crePVN-MRAP2 and Mc4r-crePVN-GFP male mice fed on HFD. Altogether these data indicate that overexpression of MRAP2 in MC4R neurons affects energy metabolism in male mice when challenged on HFD feeding.

3.4. MTII administration increases PVN cfos activation and decreases food intake of Mc4r-crePVN-GFP control male mice but does not affect Mc4r-crePVN-MRAP2 male mice. To assess the response of MTII in Mc4r-crePVN-GFP and Mc4r-crePVN-MRAP2 mice, we assessed the effect of MTII on PVN cfos immunoreactivity and food intake in male mice fed on HFD. Similar to female Mc4r-crePVN-MRAP2 mice, HFD-fed Mc4r-crePVN-MRAP2 male mice injected IP with vehicle (saline) showed a significant increase in cfos immunostaining in the PVN compared to vehicle-injected HFD-fed Mc4r-crePVN-MRAP2 male mice (46.88 ± 4.34 cfos positive cells in controls vs 63.77 ± 3.22 cfos positive cells in Mc4r-crePVN-MRAP2; n = 3 per group; Figure 6A, B and E). When MTII was injected IP in both HFD-fed Mc4r-crePVN-MRAP2 and Mc4r-crePVN-GFP male mice, no significant difference was observed (107.37 ± 10.00 cfos positive cells in controls vs 85.97 ± 13.21 cfos positive cells in Mc4r-crePVN-MRAP2; n = 6 per group; Figure 6C, D and E). In agreement with these data, significantly lower food intake was observed in HFD-fed Mc4r-crePVN-MRAP2 male mice injected with saline compared to Mc4r-crePVN-MRAP2 male mice.
injected with saline, whilst no difference in food intake was noted between Mc4r-cre<sup>PVN-GFP</sup> mice (n = 6) exposed to HFD at 2 weeks after PVN viral injections. (D and E) Graphs showing food intake in male Mc4r-cre<sup>PVN-MRAP2</sup> mice (n = 7) and Mc4r-cre<sup>PVN-GFP</sup> mice (n = 7) at 8 weeks of HFD. Cumulative food intake over a 24 h period, feeding during light and dark phases are shown. Gray area represents the dark phase. (F–I) Graphs showing locomotor activity (F), energy expenditure as a total in the 24-h cycle (G) and in the dark (h) and light (i) phases of the cycle of Mc4r-cre<sup>PVN-GFP</sup> (n = 7) and Mc4r-cre<sup>PVN-MRAP2</sup> mice (n = 7) at 8 weeks of HFD. All data are presented as mean ± SEM. *P < 0.05; **P < 0.01 compared to Mc4r-cre<sup>PVN-GFP</sup> mice.

![Figure 4: Selective overexpression of MRAP2 in PVN MC4R expressing neurons affects metabolism in male mice on HFD.](image)

Figure 4: Selective overexpression of MRAP2 in PVN MC4R expressing neurons affects metabolism in male mice on HFD. (A–C) Graphs showing body weight (A), fat mass (B) and lean mass (C) of male Mc4r-cre<sup>PVN-GFP</sup> (n = 6) and Mc4r-cre<sup>PVN-MRAP2</sup> mice (n = 6) exposed to HFD at 2 weeks after PVN viral injections. (D and E) Graphs showing food intake in male Mc4r-cre<sup>PVN-GFP</sup> (n = 7), and Mc4r-cre<sup>PVN-MRAP2</sup> mice (n = 7) at 8 weeks of HFD. Cumulative food intake over a 24 h period, feeding during light and dark phases are shown. Gray area represents the dark phase. (F–I) Graphs showing locomotor activity (F), energy expenditure as a total in the 24-h cycle (G) and in the dark (h) and light (i) phases of the cycle of Mc4r-cre<sup>PVN-GFP</sup> (n = 7) and Mc4r-cre<sup>PVN-MRAP2</sup> mice (n = 7) at 8 weeks of HFD. All data are presented as mean ± SEM. *P < 0.05; **P < 0.01 compared to Mc4r-cre<sup>PVN-GFP</sup> mice.

![Figure 5: Effects of PVN-MRAP2 overexpression on body temperature and brown adipose tissue of male mice on HFD.](image)

Figure 5: Effects of PVN-MRAP2 overexpression on body temperature and brown adipose tissue of male mice on HFD. (A) Graph showing body temperature in male Mc4r-cre<sup>PVN-GFP</sup> (n = 7) and Mc4r-cre<sup>PVN-MRAP2</sup> mice (n = 7). (B and C) Graphs showing Real-Time RT PCR data for Ucp1 (B) and Dio2 (C) in the brown adipose tissue of male Mc4r-cre<sup>PVN-GFP</sup> (n = 7) and Mc4r-cre<sup>PVN-MRAP2</sup> mice (n = 7) after 8 weeks of HFD. All data are presented as mean ± SEM. *P < 0.05 compared to Mc4r-cre<sup>PVN-GFP</sup> mice; **P < 0.01 compared to Mc4r-cre<sup>PVN-GFP</sup> mice.

4. DISCUSSION

MRAP2 has been shown to have a critical role in mammalian metabolism [4]. Mice deficient in MRAP2 have severe early-onset obesity due to increased fat mass. The mechanism of how MRAP2 knockout animals become obese without detectable changes in food intake and energy expenditure remains unclear [1,3]. Deletion of MRAP2 in Sim-1 expressing neurons leads to obesity in mice to a similar extent as in global <i>Map2<sup>−/−</sup></i> animals pointing to these neurons, located also in the PVN, as key targets of MRAP2 action in metabolism regulation [4]. Although data suggest the involvement of MC4R signaling, the difference in phenotype between the <i>Map2<sup>−/−</sup></i> and <i>Mc4r<sup>−/−</sup></i> mice...
suggest possible non-MCR modes of action [4,6]. This has since been shown to be the case. In addition to MC4R positive neurons, MRAP2 has been shown to have a broader distribution in the Central Nervous System [4,12-14,18]. Within the hypothalamus, MRAP2 has been shown to interact and regulate other GPCRs, including ghrelin receptors expressed in the arcuate Neuropeptide Y/Agouti-related (NPY/AgRP)-expressing neurons, where it positively regulates hunger signaling [13], adding to the complexity of the system.

As Sim1-Cre mice express cre activity in sites outside the PVN [8,19] and because of the critical role of PVN MC4R in the regulation of metabolism and the changes in neuropeptide transcripts observed in the PVN of global Mrap2-/- animals [6], we focused our study on investigating the role of MRAP2 in the MC4R-expressing neurons of the PVN. Our data provide evidence that MRAP2 in MC4R-expressing neurons of the PVN represents an important regulator of food intake and energy metabolism. Furthermore, the data indicate that postnatal manipulation of MRAP2 leads to changes in weight phenotype that are opposite of those observed in Mrap2-/- mice in which MRAP2 is deleted during development. By selectively overexpressing MRAP2 in MC4R neurons of the PVN, we reveal a reduction in food intake and energy expenditure that supports the observed lean phenotype, which is unlike that of Mrap2-/- in which no change in either measures were identified [4,6]. This difference could be due to action of MRAP2 on other GPCRs in the arcuate nucleus that leads to lean phenotype in the absence of MRAP2 [12-14].

In addition, unlike data on the global Mrap2-deficient mice that showed no change in BAT activation or body temperature phenotype [4,6], M4cr-crePVN-MRAP2 mice showed a significant increase in BAT activation with increased UCP1 and Dio2 mRNA levels that were associated with increased body temperature compared to control mice in both genders. We also found a sex-specific metabolic difference in the M4cr-crePVN-MRAP2 mice compared with M4cr-crePVN-GFP matched control.

Whilst female mice overexpressing MRAP2 in PVN MC4R neurons demonstrate overt protection against obesity on a chow diet, this phenotype was only observed in male mice after challenge with high fat diet. Similarly, sex differences were also observed in locomotor activity and glucose handling. We have previously described a sex-specific increase in daytime locomotor activity and exploratory activity in global Mrap2-deficient mice [6]. However, when taken in isolation, focusing on MRAP2-overexpression in PVN MC4R neurons, we now demonstrate an increase in locomotor activity in both female and male M4cr-crePVN-MRAP2 mice compared to controls. A difference in glucose clearance and hyperinsulinemia was demonstrated in Mrap2-/- mice on a C57/BL6N background, while on a 129/Sv genetic background no changes in insulin and glucose handling were found [4,6]. Others have confirmed a glucose metabolism phenotype in Mrap2-deficient mice on a C57/BL6N background [14]. In agreement with previous work, here we found differences in glucose handling when MRAP2 was manipulated. However, our data suggest that the improved glucose handling was rather a consequence of the leaner phenotype of the female M4cr-crePVN-MRAP2 mice. Indeed, no significant differences were observed in male mice on a chow diet.

To determine a possible role for POMC neurons in the regulation of PVN MC4R neurons, we then assessed the activation levels of POMC neurons by c fos immunostaining. No difference in POMC neuronal activation was observed between M4cr-crePVN-MRAP2 and controls. Furthermore, no differences were found in POMC fiber staining in the PVN of controls and M4cr-crePVN-MRAP2 mice. This suggests that the metabolic phenotype observed might be independent from changes in POMC neuronal activation, thus pointing to the increased neuronal activation in the PVN as the principal cause of the lean phenotype in the M4cr-crePVN-MRAP2 model as we observe a significant increase in c fos staining in the PVN of M4cr-crePVN-MRAP2 mice compared to controls irrespective of sex.

Figure 6: Effect of peripheral MTII administration on feeding and neuronal activation in M4cr-crePVN-GFP and M4cr-crePVN-MRAP2 male mice on HFD. (A–D) Representative hypothalamic sections immunostained for c fos (red) in male M4cr-crePVN-GFP (A and C) and male M4cr-crePVN-MRAP2 mouse (B and D) following IP injection with vehicle (saline; n = 3 per group; A and B) or MTII (n = 6 per group; C and D). (E) Quantification of c fos expression in the PVN of M4cr-crePVN-GFP and M4cr-crePVN-MRAP2 male mice injected with saline or MTII. (F) Graph showing feeding response (food intake over 24 h) after peripheral injection of vehicle (saline; n = 3 per group) or MTII (n = 6 per group) in male M4cr-crePVN-GFP and M4cr-crePVN-MRAP2 mice on HFD. 3v = third ventricle; PVN = paraventricular nucleus of the hypothalamus. Bar scale in D (for A, B, C, D) represents 100 μm. All data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to M4cr-crePVN-GFP control mice.
To assess the hypothesis that MRAP2 overexpression in MC4R neurons affect MC4R signaling, thus affecting food intake, we then administrated MTII, a MC3R/MC4R agonist, in Mc4r-cre$^{PVN-MRAP2}$ and control mice. MTII induced a significant increase in PVN neuronal activation and a reduction in feeding in male and female Mc4r-cre$^{PVN-MRAP2}$ mice. In female Mc4r-cre$^{PVN-MRAP2}$ mice MTII treatment results in further increase in PVN neuronal activation and decrease in food intake. At baseline, MRAP2 overexpression drives neuronal activation in the PVN in both males and females. However, response to MTII differed between genders; whilst female Mc4r-cre$^{PVN-MRAP2}$ mice maintained responsiveness to MTII this was lacking in male Mc4r-cre$^{PVN-MRAP2}$ mice. Altogether these results indicate that MRAP2 in PVN MC4R neurons can be manipulated postnatally to result in a lean phenotype in which feeding is reduced and energy expenditure increased along with core body temperature. Importantly, this leads to an increase in neuronal activation with in the PVN. As the number of PVN ccfos positive cells are in excess of the number of FLAG positive Mc4r-cre MRAP2 overexpressing cells, the increased ccfos would suggest a more global effect on PVN neuronal activation beyond MC4R expressing neurons. The likelihood is that the action of MRAP2 on MC4R PVN neurons is due to the action on enhancing MC4R function as much of the phenotype in Mc4r-cre$^{PVN-MRAP2}$ mice correlates to models of MC4R activation in which reduced food intake, increased energy expenditure and thermogenesis have been described [9,15]. Some other features such as sexual dimorphism of responses have not been seen in MC4R activation models. These differences could be due to estrogenic effects on MRAP2/MC4R interaction, which has been described with MRAP1 and MC2R [20,21], although action on other GPCRs expressed in MC4R expressing PVN neurons cannot be excluded.

5. CONCLUSION

In conclusion, our data provides the first evidence that MRAP2 acts postnatally, in a sex-specific manner, to play a role in the regulation of food intake and energy expenditure through the enhancement of MC4R neuronal signaling in the paraventricular nucleus of hypothalamus.

AUTHOR CONTRIBUTION

GB, JDK, and LFC conducted experiments, acquired and analyzed data. LFC and SD designed the research studies and analyzed data. GB, LFC, and SD wrote the manuscript.

ACKNOWLEDGMENTS

This work was supported by The Medical Research Council UK [MRC/Academy of Medical Sciences Clinician Scientist Fellowship Grant] G0802796 (to LFC) and NIH grants R01 DK105571, DK097566 and DK107293 (to SD).

DECLARATION OF INTEREST

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data related to this article can be found at https://doi.org/10.1016/j.molmet.2018.09.010.

REFERENCES

[1] Clark, A.J., Chan, L.F., 2017. Promiscuity among the MRAPs. Journal of Molecular Endocrinology 58: F1–F4.
[2] Liu, T., Elmquist, J.K., Williams, K.W., 2013. Mrap2: an accessory protein linked to obesity. Cell Metabolism 18:309–311.
[3] Novoselova, T.V., Chan, L.F., Clark, A.J.L., 2018. Pathophysiology of melanocortin receptors and their accessory proteins. Best Practice & Research: Clinical Endocrinology & Metabolism 32:93–106.
[4] Asai, M., Ramachandrapa, S., Joachim, M., Shen, Y., Zhang, R., Nuthalapati, N., et al., 2013. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. Science 341:275–278.
[5] Schonnop, L., Kleinag, G., Herrfurth, N., Volkmar, A.L., Cetindag, C., Muller, A., et al., 2016. Decreased melanocortin-4 receptor function conferred by an infrequent variant at the human melanocortin receptor accessory protein 2 gene. Obesity (Silver Spring) 24:1976–1982.
[6] Novoselova, T.V., Larder, R., Rimmington, D., Lelliott, C., Wynn, E.H., Gorigin, R.J., et al., 2016. Loss of Mrap2 is associated with Sim 1 deficiency and increased circulating cholesterol. Journal of Endocrinology 230(1):13–26.
[7] Sebag, J.A., Zhang, C., Hinkle, P.M., Bradshaw, A.M., Cone, R.D., 2013. Developmental control of the melanocortin-4 receptor by MRAP2 proteins in zebrafish. Science 341:278–281.
[8] Huszar, D., Lynch, C.A., Fairchild-Huntress, V., Dunmore, J.H., Fang, Q., Berkeemeier, L.R., et al., 1997. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131–141.
[9] Balthasar, N., Dalgaard, L.T., Lee, C.E., Yu, J., Furunashi, H., Williams, T., et al., 2005. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123:493–505.
[10] Marsh, D.J., Hollopeter, G., Huszar, D., Laufier, R., Yagaloff, K.A., Fisher, S.L., et al., 1999. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nature Genetics 21:119–122.
[11] Chan, L.F., Webb, T.R., Chung, T.T., Meimaridou, E., Cooray, S.N., Guasti, L., et al., 2009. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. Proceedings of the National Academy of Sciences 106:6146–6151.
[12] Chaly, A.L., Srisai, D., Gardner, E.E., Sebag, J.A., 2016. The melanocortin receptor accessory protein 2 promotes food intake through inhibition of the prokineticin receptor-1. Elife 5.
[13] Srisai, D., Yih, T.C., Lee, A.A., Rouault, A.A.J., Pearson, N.A., Grobe, J.L., et al., 2017. MRAP2 regulates ghrelin receptor signaling and hunger sensing. Nature Communications 8:713.
[14] Rouault, A.A.J., Lee, A.A., Sebag, J.A., 2017. Regions of MRAP2 required for the inhibition of orexin and prokineticin receptor signaling. Biochimica et Biophysica Acta 1864:2322–2329.
[15] Garfield, A.S., Li, C., Madara, J.C., Shah, B.P., Webber, E., Steger, J.S., et al., 2015. A neural basis for melanocortin-4 receptor-regulated appetite. Nature Neuroscience 18:863–871.
[16] Tschope, M.H., Speckman, J.R., Arch, J.R., Auwerx, J., Bruning, J.C., Chan, L., et al., 2011. A guide to analysis of mouse energy metabolism. Nature Methods 9:57–63.
[17] Kim, J.D., Toda, C., D’Agostino, G., Zeiss, C.J., D’Leon, R.J., Elsworth, J.D., et al., 2014. Hypothalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice. Proceedings of the National Academy of Sciences 111:11876–11881.
[18] Liang, J., Li, L., Jin, X., Xu, B., Pi, L., Liu, S., et al., 2018. Pharmacological effect of human melanocortin-2 receptor accessory protein 2 variants on hypothalamic melanocortin receptors. Endocrine 61:94–104.
[19] Fenselau, H., Campbell, J.N., Verstegen, A.M., Madara, J.C., Xu, J., Shah, B.P., et al., 2017. A rapidly acting glutamatergic ARC→PVH satiety circuit postsynaptically regulated by alpha-MSH. Nature Neuroscience 20:42−51.

[20] Ren, J., Li, Y., Xu, N., Li, H., Li, C., Han, R., et al., 2017. Association of estradiol on expression of melanocortin receptors and their accessory proteins in the liver of chicken (Gallus gallus). General and Comparative Endocrinology 240:182−190.

[21] Babischkin, J.S., Aberdeen, G.W., Pepe, G.J., Albrecht, E.D., 2016. Estrogen suppresses interaction of melanocortin 2 receptor and its accessory protein in the primate fetal adrenal cortex. Endocrinology 157:4588−4601.